<DOC>
	<DOCNO>NCT01123486</DOCNO>
	<brief_summary>The primary objective propose work development high resolution pharmacokinetic-pharmacodynamic ( PK-PD ) model hydromorphone experimental pain stimulus , ventilatory depression , surrogate biomarkers opioid effect allow fingerprint hydromorphone . This fingerprint serve basis development dose strategy efficiently maximize analgesia minimize ventilatory depression sedation . For example , high-resolution fingerprint allow precise estimation initial hydromorphone target effect site concentration ( Ce ) effectively administer synthetic opioids previously determine high-resolution fingerprint ( i.e. , remifentanil fentanyl ) , thereby minimize underdosing hydromorphone analgesia minimize side effect .</brief_summary>
	<brief_title>Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint</brief_title>
	<detailed_description>After 6 h fasting , volunteer 20G arterial-line place radial artery early blood sample 18 G peripheral intravenous catheter place contralateral forearm drug administration later blood sample . Continuously monitor vital sign include ECG , invasive blood pressure , hemoglobin , O2 saturation , end-tidal CO2 , respiratory rate ( capnogram ) record . After baseline PD data acquisition , bolus 0.2 mg/kg hydromorphone administer 10 sec via free-flowing peripheral IV ( t=0 ) 3 mL arterial blood sample obtain 0.25 , 0.5 , 0.75 , 1 , 1.25 , 1.5 , 1.75 , 2 min use stop-cock manifold system . Subsequent blood sample acquire 3 , 4 , 5 , 7.5 , 10 , 15 , 20 , 25 , 30 , 45 min 1 , 1.25 , 1.5 , 2 , 2.25 , 2.5 , 2.75 , 3 , 3.5 , 4 , 4.5 , 5 , 6 , 7 , 8 , 10 , 12 , 16 , 20 , 24 h. Although EEG acquire continuously , remain pharmacologic data record discrete time initial 5 min : pupillometry 1 , 2 , 5 min ; ventilation 2 min ; temperature analgesia 3 5 min , sedation level 4 min . This allow ventilation pupillometry acquire rest state , thereby limit distortion response stimulation . Subsequently , data acquire PK time point follow sequence - ventilation EEG ( simultaneously ) , pupillometry , modify OAA/S score , temperature analgesia . After 2 h , pharmacologic parameter return baseline 2 sequential measurement , record parameter stop . During study , volunteer unable use device trigger , due opioid-induced sedation , tolerance level increase temperature define temperature volunteer exhibit withdrawal movement test limb . Once data acquisition complete , volunteer allow drink clear liquid . Subsequently , diet advance tolerate . The volunteer monitor hourly ( vital sign ) Clinical Research Unit blood sample acquire .</detailed_description>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>within 20 % ideal body weight 2130 year old ASA I ( systemic disease ) No history PONV ( except wisdom teeth extraction ) No long term medication use No history coagulation defect ( i.e easy bruising , gum bleed teeth brush , frequent nose bleeds , past document coagulopathy , etc . ) Inability place arterial line A fail urine drug test admission CRU A positive pregnancy test admission CRU A hemoglobin level &lt; 12.5 g/dL admission CRU</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Intravenous opioids</keyword>
	<keyword>Patient Controlled Analgesia</keyword>
	<keyword>volunteer pharmacokinetic-pharmacodynamic study</keyword>
</DOC>